drugset
drugset / Trial / NCT01850888

MIBG for Refractory Neuroblastoma and Pheochromocytoma

NCT01850888 ↗

Completed 15 enrolled Masonic Cancer Center, University of Minnesota
NaSingle-groupOpen-labelTreatment

Summary

This is a best available therapy/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a range of doses depending on stem cell availability and tumor involvement of bone marrow. Response rate, toxicity, and time to progression and death will be evaluated.

Timeline

Start
2013-12
Primary completion
2025-10-20
Completion
2025-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject 131 I-Metaiodobenzylguanidine Unknown 10 unknown Intravenous
Subject 131 I-Metaiodobenzylguanidine Unknown 12 unknown Intravenous
Subject 131 I-Metaiodobenzylguanidine Unknown 18 unknown Intravenous
Background G-CSF Unknown 5 ug/kg Subcutaneous
Background potassium iodide Unknown 1 mg/kg Oral

Indications

neuroblastoma pheochromocytoma